Status:
COMPLETED
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Lead Sponsor:
Genentech, Inc.
Conditions:
Multiple Myeloma, Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from elig...
Eligibility Criteria
Inclusion
- Histologically confirmed solid tumors (excluding melanoma and papillary thyroid cancer) or multiple myeloma refractory to standard therapy or for which standard or curative therapy does not exist or is not considered appropriate by the investigator
- Patients with multiple myeloma must have received at least one line of prior systemic therapy for the treatment of multiple myeloma
Exclusion
- Eastern Cooperative Oncology Group (ECOG) performance status \> 2
- Uncontrolled concurrent malignancy
- Active or untreated CNS metastases
- History of known carcinomatous meningitis
- Prior treatment with a BRAF or MEK inhibitor (prior sorafenib is allowed)
- Uncontrolled, severe medical illness or condition as defined in protocol MO28072
Key Trial Info
Start Date :
December 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
662 Patients enrolled
Trial Details
Trial ID
NCT01804140
Start Date
December 1 2012
End Date
September 1 2013
Last Update
November 2 2016
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Sedona, Arizona, United States, 86336
2
Tucson, Arizona, United States, 85704
3
Burbank, California, United States, 91505
4
Rancho Cucamonga, California, United States, 91730